Ascendis Pharma

Make a delay and accumulation of outstanding tasks Full stop
Biotech

Ascendis axes IL-2 program in retreat from oncology expansion

Ascendis ended development of its IL-2 candidate, pivoting away from oncology and calling time on an asset it once tipped for accelerated approval.
Nick Paul Taylor May 7, 2026 10:10am
An arrow incrementally going up stairs before pointing straight up Blue background

AstraZeneca's $800M rare disease bet hits primary phase 3 goal

Mar 17, 2025 7:25am
Graphic of two hands shaking under a red and purple light

In $285M deal, Novo taps Ascendis to help create monthly GLP-1

Nov 4, 2024 8:43am
Graphic image of an arrow nailing the bullseye of a target

Ascendis' dwarfism drug hits in phase 3, threatens BioMarin

Sep 17, 2024 9:36am
very busy graphic of scientists working on an eye with one standing on a ladder preparing drops another set to apply a cont

Eyconis launches with $150M and Ascendis' eye disease meds

Jan 29, 2024 11:03am
Photo of two hands shaking

Ascendis sells Japan rights to Skytrofa, 2 other drugs for $70M

Nov 29, 2023 8:25am